DE3781049D1 - Verfahren zur herstellung von hepatitis-b-virus-innenkoerperantigen (hbcag) in hefe. - Google Patents

Verfahren zur herstellung von hepatitis-b-virus-innenkoerperantigen (hbcag) in hefe.

Info

Publication number
DE3781049D1
DE3781049D1 DE8787304314T DE3781049T DE3781049D1 DE 3781049 D1 DE3781049 D1 DE 3781049D1 DE 8787304314 T DE8787304314 T DE 8787304314T DE 3781049 T DE3781049 T DE 3781049T DE 3781049 D1 DE3781049 D1 DE 3781049D1
Authority
DE
Germany
Prior art keywords
hbcag
yeast
imperantigens
hepatitis
internal body
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787304314T
Other languages
English (en)
Other versions
DE3781049T2 (de
Inventor
Ronald W Ellis
Arpi Hagopian
Peter J Kniskern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of DE3781049D1 publication Critical patent/DE3781049D1/de
Application granted granted Critical
Publication of DE3781049T2 publication Critical patent/DE3781049T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Peptides Or Proteins (AREA)
DE8787304314T 1986-05-23 1987-05-15 Verfahren zur herstellung von hepatitis-b-virus-innenkoerperantigen (hbcag) in hefe. Expired - Fee Related DE3781049T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86655886A 1986-05-23 1986-05-23

Publications (2)

Publication Number Publication Date
DE3781049D1 true DE3781049D1 (de) 1992-09-17
DE3781049T2 DE3781049T2 (de) 1993-03-04

Family

ID=25347871

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787304314T Expired - Fee Related DE3781049T2 (de) 1986-05-23 1987-05-15 Verfahren zur herstellung von hepatitis-b-virus-innenkoerperantigen (hbcag) in hefe.

Country Status (6)

Country Link
EP (1) EP0251460B1 (de)
JP (1) JPS6332491A (de)
AT (1) ATE79404T1 (de)
DE (1) DE3781049T2 (de)
DK (1) DK257887A (de)
IE (1) IE59389B1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010300A1 (en) * 1987-06-22 1988-12-29 Medico Labs Ag Heterologous viral peptide particle immunogens
US4963483A (en) * 1987-10-13 1990-10-16 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
JP4895281B2 (ja) * 2006-10-16 2012-03-14 日本電産リード株式会社 コネクタ

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3381619D1 (de) * 1982-08-16 1990-07-05 Chemo Sero Therapeut Res Inst Pendelvektor.
EP0174444B1 (de) * 1984-06-18 1992-03-11 Chiron Corporation Hepatitisoberflächenantigenpartikelvakzin

Also Published As

Publication number Publication date
EP0251460A3 (en) 1988-07-20
JPS6332491A (ja) 1988-02-12
DK257887D0 (da) 1987-05-21
IE871224L (en) 1987-11-23
ATE79404T1 (de) 1992-08-15
DK257887A (da) 1987-11-24
IE59389B1 (en) 1994-12-23
EP0251460B1 (de) 1992-08-12
DE3781049T2 (de) 1993-03-04
EP0251460A2 (de) 1988-01-07

Similar Documents

Publication Publication Date Title
DE3689447D1 (de) Rekombinantes Viren-Überzugsprotein assoziiert mit "Acquired Immune Deficiency Syndrome" (AIDS) und Verfahren zur Testung von AIDS.
PT97159A (pt) Processo para a preparacao de uma proteina do antigenio de superficie da hepatite b ou de um seu fragmento e processo para a preparacao de uma vacina
AU697743C (en) Papillomavirus vaccines
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
ATE298800T1 (de) Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
ATE187775T1 (de) Verfahren zur herstellung von menschlichem serumalbumin in hefe
ATE61228T1 (de) Immunogener protein- oder peptidkomplex, verfahren zur herstellung dieses komplexes und seine verwendung als immunstimulans und als impfstoff.
ATE430200T1 (de) Impstoff gegen den für atemwegs- und reproduktionserkrankungen beim schwein verantwortlichen virus
CA2116348A1 (en) Sirs vaccine and diagnosis method
ES2013346A6 (es) Metodos para producir secuencias y moleculas de adn recombinante, asi como proteinas t4 solubles.
DE3773963D1 (de) Verfahren zur herstellung von reifem, menschlichem serum-albumin.
DE69030383D1 (de) Impfstoff-Konjugate zur Behandlung von Vogelkrankheiten
ATE2442T1 (de) Verfahren zur herstellung von interferon und dabei verwendete kulturmediumzusammensetzung.
DE3781049D1 (de) Verfahren zur herstellung von hepatitis-b-virus-innenkoerperantigen (hbcag) in hefe.
EP0289550A4 (de) Impfstoff zur behandlung von hsv.
EP0236977A3 (de) Impfstoffe gegen Rindervirus-Diarrhoe und Schweine-Cholera
EP0344864A3 (de) Verfahren zur Herstellung von nicht-hyperglycosylierten Hepatitis B Virusproteinen
NO912942L (no) Vaksine for preventiv behandling av infeksjon av leverikte hos droevtyggere.
HU9200583D0 (en) Method for producing el peptides of rubeola
PT91316A (pt) Processo para a preparacao de vectores recombinantes e de particulas hbsag recombinantes hibridas tendo as caracteristicas morfologicas do antigenio hbsag contendo uma sequencia imunogenica que induz anticorpos neutralizantes dirigidos contra hiv ou susceptivel de ser reconhecida por tais anticorpos
ATE3058T1 (de) Herpes-virus-impfstoff und seine herstellung.
ATE7267T1 (de) Impfstoff und verfahren zu seiner herstellung.
NZ230996A (en) Immunogenic recombinant polypeptides and their use in the production of neutralising antibodies against viral haemorrhagic septicaemia virus
EP0503252A3 (en) Recombinant proteins having the immunoreactivity of hepatitis b virus e antigens (hbeag), method for their production and their application in immunoassays and as vaccines
IL78343A0 (en) Newcastle's disease virus(ndv)vaccine and method for the application thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee